On July 15, XtalPi Holdings rose 5.38% in regular trading, trading at HK$7.77/share, with turnover of HK$105 million. The Life Sciences Tools & Services sector saw broad-based gains, with JOINN up 13.06%, Insilico Medicine up 8.05%, Wuxi Biologics up 4.97%, Wuxi AppTec up 4.87%, and Pharmaron up 4.83%.

On the catalyst front, Guohai Securities recently initiated coverage on XtalPi with an Overweight rating, highlighting the company's AI + Robotics + Multi-Agent R&D paradigm as a core growth driver. The broker projects revenues of RMB 1.033/1.398/1.815 billion for 2026/2027/2028, with net profit forecast at RMB 0.04/0.89/2.35 billion respectively. The company delivered a strong turnaround in full-year results, with revenue reaching RMB 803 million, up over 200% year-over-year, while swinging to a profit of RMB 135 million versus a prior-year loss of RMB 1.515 billion.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)